NO20092774L - HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette - Google Patents

HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette

Info

Publication number
NO20092774L
NO20092774L NO20092774A NO20092774A NO20092774L NO 20092774 L NO20092774 L NO 20092774L NO 20092774 A NO20092774 A NO 20092774A NO 20092774 A NO20092774 A NO 20092774A NO 20092774 L NO20092774 L NO 20092774L
Authority
NO
Norway
Prior art keywords
peptide
hla
amino acid
restricted
pharmaceutical composition
Prior art date
Application number
NO20092774A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of NO20092774L publication Critical patent/NO20092774L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)

Abstract

Beskrevet er: Et HLA-A*1101 begrenset WT1-peptid, spesifikt et peptid som omfatter en aminosyresekvens som består av 9 sammenhengende aminosyreresidier som er avledet fra WT1-protein, som er i stand til å binde til et HLA-A*1101-molekyl og har en CTL-induserende evne; som en peptid-dimer som omfatter to peptidmonomerer som hver omfatter en aminosyresekvens som består av 9 sammenhengende aminosyreresidier, som inneholder minst en cysteinresidie og er avledet fra WT1-protein, hvori de to peptidmonomerene er koblet til hverandre via en disulfidbinding, og peptid-dimeren er i stand til å binde til et HLAA*1101-molekyl og har en CTL-induserende evne; et polynukleotid som koder for peptidet; et farmasøytisk preparat for behandling og/eller forhindring av kreft, som omfatter peptidet eller peptid-dimeren; og andre.
NO20092774A 2006-12-28 2009-07-27 HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette NO20092774L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28
PCT/JP2007/074146 WO2008081701A1 (ja) 2006-12-28 2007-12-14 Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
NO20092774L true NO20092774L (no) 2009-07-27

Family

ID=39588385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092774A NO20092774L (no) 2006-12-28 2009-07-27 HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette

Country Status (28)

Country Link
US (4) US8653038B2 (no)
EP (6) EP3026115B1 (no)
JP (1) JP5484734B2 (no)
KR (1) KR101525261B1 (no)
CN (5) CN101573448B (no)
AR (1) AR064555A1 (no)
AU (1) AU2007340679B2 (no)
BR (1) BRPI0720988A2 (no)
CA (5) CA2886621A1 (no)
CY (1) CY1116011T1 (no)
DK (3) DK2341142T3 (no)
ES (4) ES2629578T3 (no)
HK (3) HK1173187A1 (no)
IL (4) IL199052A0 (no)
MX (1) MX2009007008A (no)
MY (1) MY161664A (no)
NO (1) NO20092774L (no)
NZ (4) NZ592510A (no)
PH (1) PH12014500902B1 (no)
PL (1) PL2341142T3 (no)
PT (1) PT2341142E (no)
RU (1) RU2481398C2 (no)
SG (1) SG177222A1 (no)
SI (1) SI2341142T1 (no)
TW (3) TWI554280B (no)
UA (1) UA103154C2 (no)
WO (1) WO2008081701A1 (no)
ZA (1) ZA200903633B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378264T3 (es) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CN103103246B (zh) 2007-02-27 2018-05-01 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
WO2012046730A1 (ja) * 2010-10-05 2012-04-12 国立大学法人大阪大学 ヘルパーｔ細胞の活性化方法
MY160662A (en) * 2011-04-01 2017-03-15 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
BR112014002747A2 (pt) * 2011-09-14 2020-10-27 International Institute Of Cancer Immunology, Inc método para medir um anticorpo anti-wt1
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
KR20150046346A (ko) 2012-09-12 2015-04-29 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 항원 특이적 헬퍼 t 세포 리셉터 유전자
KR102208505B1 (ko) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 고처리량 수용체:리간드 확인을 위한 방법
EP2933261B1 (en) * 2012-12-17 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
RU2014102945A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция
JP6512569B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤
CA2840974A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
CN103961306A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
MX364459B (es) * 2013-03-29 2019-04-26 Sumitomo Dainippon Pharma Co Ltd Vacuna de conjugado de péptido-antígeno de wt1.
JP6671956B2 (ja) * 2013-03-29 2020-03-25 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
US10525096B2 (en) 2014-12-11 2020-01-07 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017379900A1 (en) 2016-12-22 2019-06-13 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
US20200368338A1 (en) * 2017-12-27 2020-11-26 Sumitomo Dainippon Pharma Co., Ltd. Conjugate of wt1-derived peptides and composition comprising the same
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
MY139226A (en) * 1998-09-30 2009-08-28 Corixa Corp Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
CZ20013527A3 (cs) * 1999-04-02 2002-10-16 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
AU2001247220A1 (en) 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
TWI318630B (en) * 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
CN101113163B (zh) 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20060217297A1 (en) * 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Also Published As

Publication number Publication date
TWI599367B (zh) 2017-09-21
ES2629578T3 (es) 2017-08-11
EP3026115B1 (en) 2017-05-17
AU2007340679A1 (en) 2008-07-10
HK1173187A1 (zh) 2013-05-10
EP2980219A1 (en) 2016-02-03
IL215332A0 (en) 2011-11-30
ES2554775T3 (es) 2015-12-23
ES2556831T3 (es) 2016-01-20
TW201630620A (zh) 2016-09-01
SG177222A1 (en) 2012-01-30
CN102302788A (zh) 2012-01-04
CN102335439A (zh) 2012-02-01
MX2009007008A (es) 2009-07-10
BRPI0720988A2 (pt) 2014-03-18
JPWO2008081701A1 (ja) 2010-04-30
UA103154C2 (uk) 2013-09-25
TWI554280B (zh) 2016-10-21
EP2098595A4 (en) 2010-03-17
NZ577443A (en) 2011-12-22
EP2980219B1 (en) 2018-11-14
EP2341142A2 (en) 2011-07-06
TW201345544A (zh) 2013-11-16
CA2886620A1 (en) 2008-07-10
DK2479276T3 (en) 2015-12-21
RU2481398C2 (ru) 2013-05-10
DK2479275T3 (en) 2015-12-14
US20160199472A1 (en) 2016-07-14
CA2886621A1 (en) 2008-07-10
CA2886619A1 (en) 2008-07-10
CN102295682A (zh) 2011-12-28
KR20090102772A (ko) 2009-09-30
PH12014500902A1 (en) 2016-01-11
HK1159686A1 (en) 2012-08-03
US9272026B2 (en) 2016-03-01
IL215333A0 (en) 2011-11-30
NZ592510A (en) 2012-11-30
US20180064795A1 (en) 2018-03-08
AR064555A1 (es) 2009-04-08
CN102302788B (zh) 2016-06-15
EP2341142A3 (en) 2011-09-07
CA2670658A1 (en) 2008-07-10
EP2098595A1 (en) 2009-09-09
EP2479276A1 (en) 2012-07-25
HK1221252A1 (zh) 2017-05-26
CN102659924A (zh) 2012-09-12
WO2008081701A1 (ja) 2008-07-10
TWI417103B (zh) 2013-12-01
EP3026115A1 (en) 2016-06-01
CA2886622A1 (en) 2008-07-10
MY161664A (en) 2017-04-28
US20140134200A1 (en) 2014-05-15
JP5484734B2 (ja) 2014-05-07
US20110098233A1 (en) 2011-04-28
IL215334A0 (en) 2011-11-30
PT2341142E (pt) 2015-02-13
IL199052A0 (en) 2010-03-28
NZ601175A (en) 2012-12-21
TW200835513A (en) 2008-09-01
AU2007340679B2 (en) 2013-09-12
US8653038B2 (en) 2014-02-18
KR101525261B1 (ko) 2015-06-02
EP2341142B1 (en) 2014-11-26
CY1116011T1 (el) 2017-01-25
PL2341142T3 (pl) 2015-04-30
CN102335439B (zh) 2015-04-22
EP2479275A1 (en) 2012-07-25
SI2341142T1 (sl) 2015-03-31
RU2009128979A (ru) 2011-02-10
EP2341142B8 (en) 2015-01-14
EP2479276B1 (en) 2015-12-09
NZ592509A (en) 2012-11-30
DK2341142T3 (en) 2014-12-08
ZA200903633B (en) 2010-02-24
ES2526425T3 (es) 2015-01-12
CN102659924B (zh) 2015-11-25
PH12014500902B1 (en) 2016-01-11
CN101573448B (zh) 2012-07-11
CN101573448A (zh) 2009-11-04
EP2479275B1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
TWI666026B (zh) Ｗｔ１抗原胜肽結合疫苗
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
ATE517118T1 (de) Bis-met-histone
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
PE20120021A1 (es) Mutantes fgf21
PE20140159A1 (es) Coagonistas del receptor de glucagon/glp-1
JP2013543497A5 (no)
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
DK2010563T3 (da) Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
EA201100071A1 (ru) Новые композиции и способы
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
ATE532502T1 (de) Kosmetische zusammensetzung für das haar
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
BR112017019241A2 (pt) análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application